Eli Lilly and Company (LLY)
- Previous Close
750.77 - Open
749.42 - Bid --
- Ask --
- Day's Range
743.77 - 752.20 - 52 Week Range
370.68 - 800.78 - Volume
1,701,144 - Avg. Volume
3,050,669 - Market Cap (intraday)
709.224B - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
128.17 - EPS (TTM)
5.82 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield 5.20 (0.70%)
- Ex-Dividend Date Feb 14, 2024
- 1y Target Est
826.94
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
www.lilly.com43,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LLY
Related Videos: LLY
Performance Overview: LLY
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LLY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LLY
Valuation Measures
Market Cap
709.22B
Enterprise Value
731.52B
Trailing P/E
128.61
Forward P/E
59.88
PEG Ratio (5yr expected)
1.42
Price/Sales (ttm)
19.75
Price/Book (mrq)
65.84
Enterprise Value/Revenue
21.44
Enterprise Value/EBITDA
85.38
Financial Highlights
Profitability and Income Statement
Profit Margin
15.36%
Return on Assets (ttm)
11.88%
Return on Equity (ttm)
48.44%
Revenue (ttm)
34.12B
Net Income Avi to Common (ttm)
5.24B
Diluted EPS (ttm)
5.82
Balance Sheet and Cash Flow
Total Cash (mrq)
3.04B
Total Debt/Equity (mrq)
243.63%
Levered Free Cash Flow (ttm)
236.88M
Research Analysis: LLY
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: LLY
Technical Assessment: Neutral in the Intermediate-Term
Overnight events in the Middle East notwithstanding, WTI closed yesterday at $82.05/barrel, down slightly and below its recent high on April 5 and April 12 near $88. Crude oil traced out a bearish throwback, as its breakout over the top of the bullish channel that has been in place for about four months failed miserably. Generally, failed breakouts and failed breakdowns lead to decent-sized moves in the other direction. Almost the entire rally from the high $60s was labored and failed to generate much enthusiasm among market participants.
Analyst Report: Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
RatingBearishPrice TargetTechnical Assessment: Neutral in the Intermediate-Term
It was another week of all-time highs, with the weekly winning streak for the S&P 500 (SPX) continuing. The SPX has moved higher in 17 out of 21 weeks, with a 27% gain during that period. The Nasdaq 100 (QQQ) and the Nasdaq are also 17 out of 21, soaring 30%. The S&P 400 prints the same story, with a 29% pop. Index price volatility is almost undetectable, although there has been some decent volatility, both up and down, among individual stocks. We saw one day of strong breadth on Wednesday and one weak day on Friday.
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.